PT-141

PT-141 (bremelanotide) is primarily investigated and used for the treatment of hypoactive sexual desire disorder (HSDD) in women. The compound has undergone clinical development through Phase 2 and Phase 3 trials, with completed studies focusing specifically on premenopausal women with sexual dysfunction.

Primary Clinical Application

Hypoactive Sexual Desire Disorder in Women: PT-141 has been evaluated in multiple clinical trials for treating HSDD in premenopausal women. Three completed clinical trials (NCT02338960, NCT02333071, and NCT01382719) have assessed its efficacy and safety profile for this indication. Two Phase 3 studies specifically evaluated PT-141's effectiveness in premenopausal women with HSDD, while an earlier Phase 2 trial examined its use in women with both female sexual arousal disorder and HSDD.

Emerging Applications Under Investigation

Recent systematic reviews suggest PT-141 is being examined as part of the broader landscape of emerging pharmacological therapies for female sexual dysfunction. The compound is also being considered within the context of therapeutic peptides that may have applications in:

• Aesthetic, metabolic, and endocrine conditions as part of the therapeutic peptide class
• Gerontology applications for healthy aging, though specific evidence for PT-141 in this context is limited
• Sexual health concerns in cancer survivors, particularly after breast and gynecologic cancer, though direct evidence for PT-141 in this population is not established

Potential Male Applications

There is emerging interest in whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, though the clinical evidence base for this application appears to be in early development compared to the female HSDD indication.

Evidence Limitations

While PT-141 has completed Phase 3 trials for female HSDD, the available evidence primarily focuses on premenopausal women. The broader applications in metabolic conditions, aging, and male sexual dysfunction require further clinical investigation to establish efficacy and safety profiles in these populations.

This information is for educational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.